The majority of endometrial cancers are diagnosed in early stages and treated with surgery alone. Treatment options for patients with advanced or recurrent disease remain limited to paclitaxel/carboplatin and thus current development is heavily focused on advanced/recurrent disease. Immune checkpoint inhibitors are poised to change the treatment landscape as combinations with chemotherapy dominate development in the front-line setting, with pembrolizumab already approved in 2nd-line for dMMR and TMB-H (tumor mutation burden- high) endometrial cancer.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Endometrial Cancers to help guide strategic and tactical commercial development decisions for market participants.